2010
DOI: 10.1111/j.1349-7006.2009.01472.x
|View full text |Cite
|
Sign up to set email alerts
|

Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: Different mortality but similar recurrence

Abstract: The purpose was to ascertain whether the recurrence risk patterns for patients with estrogen receptor (ER)-positive (P) and ER-negative (N) breast cancer support the ER-related clinical divergence suggested by the observed different mortality patterns and gene expression profiles. Both recurrence and death were considered in a series of 771 patients undergoing mastectomy. ER status was available for 539 patients. The hazard rates for recurrence and mortality throughout 15 years of follow-up were assessed. The … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

5
34
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 32 publications
(40 citation statements)
references
References 35 publications
5
34
1
Order By: Relevance
“…This is the first use of the extensive SEER-Medicare data to describe the changes of hazard on recurrence timing for women with breast cancer, and the results from this study are comparable with the results of early studies from different patient populations (11)(12)(13)(14)(15)(16)(17)(18)(19). We did not observe evidence for a secondary peak in the distribution of hazard curves in our patient population, as reported in earlier studies (14,29). Earlier studies included women with tumor stage I through stage IV and did not stratify by stage when calculating the HR over follow-up time.…”
Section: Discussionsupporting
confidence: 89%
“…This is the first use of the extensive SEER-Medicare data to describe the changes of hazard on recurrence timing for women with breast cancer, and the results from this study are comparable with the results of early studies from different patient populations (11)(12)(13)(14)(15)(16)(17)(18)(19). We did not observe evidence for a secondary peak in the distribution of hazard curves in our patient population, as reported in earlier studies (14,29). Earlier studies included women with tumor stage I through stage IV and did not stratify by stage when calculating the HR over follow-up time.…”
Section: Discussionsupporting
confidence: 89%
“…As reported in the literature, the recurrence rate after surgery shows a nonlinear time trend, with a first peak of relapse after 2Y3 years and a second peak after 5Y6 years from the diagnosis, independent of the expression of hormone receptors in the primary tumor. 29 Moreover, the risk of early relapse is higher in patients with no receptor expression, while late relapse is more frequent in patients with a positive receptor tumor. 30,31 Therefore, the withdrawal of HT in this unsteady period could be hazardous to the patient's health.…”
Section: Discussionmentioning
confidence: 99%
“…The piecewise exponential model was often utilized for flexible modelling of the hazard function [8,9]. However, it requires choosing a suitable partition of the follow-up time and of the spline function's complexity.…”
Section: Discussionmentioning
confidence: 99%